We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Primary CNS lymphoma.
Seminars in Oncology 1999 June
Primary CNS lymphoma (PCNSL) is seen with increasing frequency in both immunocompetent and immunocompromised patients. Radiation therapy has historically been standard treatment for this disease, resulting in complete remissions in the majority of patients, but with most patients relapsing and dying of the disease in less than 2 years. The use of chemotherapy appears to be changing the natural history of this tumor, with significantly prolonged survival in some groups of patients. The optimal agents, doses, schedules, routes of administration, and need for radiation therapy, however, remain undefined. In this review, some of the questions regarding the management of PCNSL are addressed and recommendations are made regarding the design of future regimens.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app